Deferasirox

DB01609

small molecule approved investigational

Deskripsi

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Struktur Molekul 2D

Berat 373.3615
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean elimination half-life ranged from 8 to 16 hours following oral administration.
Volume Distribusi * 14.37 ± 2.69 L
Klirens (Clearance) -

Absorpsi

The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.

Metabolisme

Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.

Rute Eliminasi

Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).

Interaksi Makanan

3 Data
  • 1. Take at the same time every day.
  • 2. Take on an empty stomach. Take at least 30 minutes before food.
  • 3. Take separate from meals. Administration with food causes inconsistent bioavailability. May administer granules with a light meal, if necessary.

Interaksi Obat

825 Data
Lepirudin The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.
Bivalirudin The risk or severity of gastrointestinal bleeding can be increased when Bivalirudin is combined with Deferasirox.
Alteplase The risk or severity of gastrointestinal bleeding can be increased when Alteplase is combined with Deferasirox.
Urokinase The risk or severity of gastrointestinal bleeding can be increased when Urokinase is combined with Deferasirox.
Reteplase The risk or severity of gastrointestinal bleeding can be increased when Reteplase is combined with Deferasirox.
Anistreplase The risk or severity of gastrointestinal bleeding can be increased when Anistreplase is combined with Deferasirox.
Tenecteplase The risk or severity of gastrointestinal bleeding can be increased when Tenecteplase is combined with Deferasirox.
Abciximab The risk or severity of gastrointestinal bleeding can be increased when Abciximab is combined with Deferasirox.
Drotrecogin alfa The risk or severity of gastrointestinal bleeding can be increased when Drotrecogin alfa is combined with Deferasirox.
Streptokinase The risk or severity of gastrointestinal bleeding can be increased when Streptokinase is combined with Deferasirox.
Dicoumarol The risk or severity of gastrointestinal bleeding can be increased when Dicoumarol is combined with Deferasirox.
Argatroban The risk or severity of gastrointestinal bleeding can be increased when Argatroban is combined with Deferasirox.
Ardeparin The risk or severity of gastrointestinal bleeding can be increased when Ardeparin is combined with Deferasirox.
Phenindione The risk or severity of gastrointestinal bleeding can be increased when Phenindione is combined with Deferasirox.
Fondaparinux The risk or severity of gastrointestinal bleeding can be increased when Fondaparinux is combined with Deferasirox.
Warfarin The risk or severity of gastrointestinal bleeding can be increased when Warfarin is combined with Deferasirox.
Pentosan polysulfate The risk or severity of gastrointestinal bleeding can be increased when Pentosan polysulfate is combined with Deferasirox.
Phenprocoumon The risk or severity of gastrointestinal bleeding can be increased when Phenprocoumon is combined with Deferasirox.
Dipyridamole The risk or severity of gastrointestinal bleeding can be increased when Dipyridamole is combined with Deferasirox.
Heparin The risk or severity of gastrointestinal bleeding can be increased when Heparin is combined with Deferasirox.
Enoxaparin The risk or severity of gastrointestinal bleeding can be increased when Enoxaparin is combined with Deferasirox.
Epoprostenol The risk or severity of gastrointestinal bleeding can be increased when Epoprostenol is combined with Deferasirox.
Acenocoumarol The risk or severity of gastrointestinal bleeding can be increased when Acenocoumarol is combined with Deferasirox.
4-hydroxycoumarin The risk or severity of gastrointestinal bleeding can be increased when 4-hydroxycoumarin is combined with Deferasirox.
Coumarin The risk or severity of gastrointestinal bleeding can be increased when Coumarin is combined with Deferasirox.
Ximelagatran The risk or severity of gastrointestinal bleeding can be increased when Ximelagatran is combined with Deferasirox.
Desmoteplase The risk or severity of gastrointestinal bleeding can be increased when Desmoteplase is combined with Deferasirox.
Defibrotide The risk or severity of gastrointestinal bleeding can be increased when Defibrotide is combined with Deferasirox.
Ancrod The risk or severity of gastrointestinal bleeding can be increased when Ancrod is combined with Deferasirox.
Beraprost The risk or severity of gastrointestinal bleeding can be increased when Beraprost is combined with Deferasirox.
Prasugrel The risk or severity of gastrointestinal bleeding can be increased when Prasugrel is combined with Deferasirox.
Rivaroxaban The risk or severity of gastrointestinal bleeding can be increased when Rivaroxaban is combined with Deferasirox.
Sulodexide The risk or severity of gastrointestinal bleeding can be increased when Sulodexide is combined with Deferasirox.
Semuloparin The risk or severity of gastrointestinal bleeding can be increased when Semuloparin is combined with Deferasirox.
Idraparinux The risk or severity of gastrointestinal bleeding can be increased when Idraparinux is combined with Deferasirox.
Cangrelor The risk or severity of gastrointestinal bleeding can be increased when Cangrelor is combined with Deferasirox.
Astaxanthin The risk or severity of gastrointestinal bleeding can be increased when Astaxanthin is combined with Deferasirox.
Apixaban The risk or severity of gastrointestinal bleeding can be increased when Apixaban is combined with Deferasirox.
Otamixaban The risk or severity of gastrointestinal bleeding can be increased when Otamixaban is combined with Deferasirox.
Amediplase The risk or severity of gastrointestinal bleeding can be increased when Amediplase is combined with Deferasirox.
Dabigatran etexilate The risk or severity of gastrointestinal bleeding can be increased when Dabigatran etexilate is combined with Deferasirox.
Danaparoid The risk or severity of gastrointestinal bleeding can be increased when Danaparoid is combined with Deferasirox.
Dalteparin The risk or severity of gastrointestinal bleeding can be increased when Dalteparin is combined with Deferasirox.
Tinzaparin The risk or severity of gastrointestinal bleeding can be increased when Tinzaparin is combined with Deferasirox.
(R)-warfarin The risk or severity of gastrointestinal bleeding can be increased when (R)-warfarin is combined with Deferasirox.
Ethyl biscoumacetate The risk or severity of gastrointestinal bleeding can be increased when Ethyl biscoumacetate is combined with Deferasirox.
Nadroparin The risk or severity of gastrointestinal bleeding can be increased when Nadroparin is combined with Deferasirox.
Triflusal The risk or severity of gastrointestinal bleeding can be increased when Triflusal is combined with Deferasirox.
Ticagrelor The risk or severity of gastrointestinal bleeding can be increased when Ticagrelor is combined with Deferasirox.
Ditazole The risk or severity of gastrointestinal bleeding can be increased when Ditazole is combined with Deferasirox.
Vorapaxar The risk or severity of gastrointestinal bleeding can be increased when Vorapaxar is combined with Deferasirox.
Edoxaban The risk or severity of gastrointestinal bleeding can be increased when Edoxaban is combined with Deferasirox.
Sodium citrate The risk or severity of gastrointestinal bleeding can be increased when Sodium citrate is combined with Deferasirox.
Dextran The risk or severity of gastrointestinal bleeding can be increased when Dextran is combined with Deferasirox.
Bemiparin The risk or severity of gastrointestinal bleeding can be increased when Bemiparin is combined with Deferasirox.
Parnaparin The risk or severity of gastrointestinal bleeding can be increased when Parnaparin is combined with Deferasirox.
Desirudin The risk or severity of gastrointestinal bleeding can be increased when Desirudin is combined with Deferasirox.
Antithrombin Alfa The risk or severity of gastrointestinal bleeding can be increased when Antithrombin Alfa is combined with Deferasirox.
Protein C The risk or severity of gastrointestinal bleeding can be increased when Protein C is combined with Deferasirox.
Antithrombin III human The risk or severity of gastrointestinal bleeding can be increased when Antithrombin III human is combined with Deferasirox.
Letaxaban The risk or severity of gastrointestinal bleeding can be increased when Letaxaban is combined with Deferasirox.
Darexaban The risk or severity of gastrointestinal bleeding can be increased when Darexaban is combined with Deferasirox.
Betrixaban The risk or severity of gastrointestinal bleeding can be increased when Betrixaban is combined with Deferasirox.
Nafamostat The risk or severity of gastrointestinal bleeding can be increased when Nafamostat is combined with Deferasirox.
Monteplase The risk or severity of gastrointestinal bleeding can be increased when Monteplase is combined with Deferasirox.
Gabexate The risk or severity of gastrointestinal bleeding can be increased when Gabexate is combined with Deferasirox.
Fluindione The risk or severity of gastrointestinal bleeding can be increased when Fluindione is combined with Deferasirox.
Protein S human The risk or severity of gastrointestinal bleeding can be increased when Protein S human is combined with Deferasirox.
Brinase The risk or severity of gastrointestinal bleeding can be increased when Brinase is combined with Deferasirox.
Clorindione The risk or severity of gastrointestinal bleeding can be increased when Clorindione is combined with Deferasirox.
Diphenadione The risk or severity of gastrointestinal bleeding can be increased when Diphenadione is combined with Deferasirox.
Tioclomarol The risk or severity of gastrointestinal bleeding can be increased when Tioclomarol is combined with Deferasirox.
Melagatran The risk or severity of gastrointestinal bleeding can be increased when Melagatran is combined with Deferasirox.
Saruplase The risk or severity of gastrointestinal bleeding can be increased when Saruplase is combined with Deferasirox.
(S)-Warfarin The risk or severity of gastrointestinal bleeding can be increased when (S)-Warfarin is combined with Deferasirox.
Tocopherylquinone The risk or severity of gastrointestinal bleeding can be increased when Tocopherylquinone is combined with Deferasirox.
Dabigatran The risk or severity of gastrointestinal bleeding can be increased when Dabigatran is combined with Deferasirox.
Troxerutin The risk or severity of gastrointestinal bleeding can be increased when Troxerutin is combined with Deferasirox.
Edetic acid The risk or severity of gastrointestinal bleeding can be increased when Edetic acid is combined with Deferasirox.
Reviparin The risk or severity of gastrointestinal bleeding can be increased when Reviparin is combined with Deferasirox.
Dermatan sulfate The risk or severity of gastrointestinal bleeding can be increased when Dermatan sulfate is combined with Deferasirox.
SR-123781A The risk or severity of gastrointestinal bleeding can be increased when SR-123781A is combined with Deferasirox.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Deferasirox.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Deferasirox.
Azelastine The serum concentration of Azelastine can be increased when it is combined with Deferasirox.
Fluvoxamine The serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.
Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Deferasirox.
Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
Caffeine The serum concentration of Caffeine can be increased when it is combined with Deferasirox.
Carmustine The serum concentration of Carmustine can be increased when it is combined with Deferasirox.
Theophylline The serum concentration of Theophylline can be increased when it is combined with Deferasirox.
Disopyramide The serum concentration of Disopyramide can be increased when it is combined with Deferasirox.
Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Deferasirox.
Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Deferasirox.
Ropivacaine The serum concentration of Ropivacaine can be increased when it is combined with Deferasirox.
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Deferasirox.
Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Deferasirox.
Olanzapine The serum concentration of Olanzapine can be increased when it is combined with Deferasirox.
Chlorzoxazone The serum concentration of Chlorzoxazone can be increased when it is combined with Deferasirox.
Clozapine The serum concentration of Clozapine can be decreased when it is combined with Deferasirox.

Target Protein

Iron

Referensi & Sumber

Synthesis reference: Rajendra Suryabhan Patil, Kishore Charugundla, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson, "SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF." U.S. Patent US20110171138, issued July 14, 2011.

Contoh Produk & Brand

Produk: 223 • International brands: 0
Produk
  • Apo-deferasirox
    Tablet, for suspension • 125 mg • Oral • Canada • Generic • Approved
  • Apo-deferasirox
    Tablet, for suspension • 250 mg • Oral • Canada • Generic • Approved
  • Apo-deferasirox
    Tablet, for suspension • 500 mg • Oral • Canada • Generic • Approved
  • Apo-deferasirox (type J)
    Tablet • 90 mg • Oral • Canada • Generic • Approved
  • Apo-deferasirox (type J)
    Tablet • 180 mg • Oral • Canada • Generic • Approved
  • Apo-deferasirox (type J)
    Tablet • 360 mg • Oral • Canada • Generic • Approved
  • Auro-deferasirox (type J)
    Tablet • 90 mg • Oral • Canada • Generic • Approved
  • Auro-deferasirox (type J)
    Tablet • 180 mg • Oral • Canada • Generic • Approved
Menampilkan 8 dari 223 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul